NICE backs Novartis' Kymriah in acute lymphoblastic leukemia
U.K.'s NICE recommended in final guidance CAR T therapy Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) for use through the Cancer Drug Fund in patients under 25 with relapsed or refractory B cell acute lymphoblastic leukemia. NICE said Novartis agreed to a undisclosed discount to Kymriah's list price of £282,000 ($362,679).
The announcement comes two months after Novartis and NHS England reached an agreement to make Kymriah available in what the agency said was Europe’s first full access deal for a CAR T therapy. NICE said NHS England will make Kymriah available in the coming weeks, with about 25-30 patients eligible for treatment each year (see "Kymriah Becomes First CAR T Available on NHS England")...